Press Releases

07.01.2020

Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 study of mRNA-based Vaccine Candidate Against SARS-CoV-2

06.30.2020

FDA Approves BAVENCIO as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carcinoma

06.30.2020

European Commission Approves DAURISMO™ (glasdegib) for Certain Adult Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

06.25.2020

Pfizer Declares Third-Quarter 2020 Dividend

06.24.2020

Pfizer and Wellcome Launch Surveillance Program to Combat Growing Threat of Antimicrobial Resistance in Sub-Saharan Africa

06.22.2020

European Medicines Agency Validates Application for BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma

06.22.2020

Pfizer Announces Start of Four Phase 3 Clinical Trials for Investigational Vaccines

06.22.2020

European Medicines Agency Validates Application for BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma

06.18.2020

Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (SB-525) Gene Therapy

06.18.2020

Upjohn Announces Pricing of Senior Notes in Connection with the Proposed Combination of Mylan and Upjohn

06.16.2020

Pfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Analysts

06.12.2020

Pfizer Invites Public to View and Listen to Webcast of June 18 Conference Call with Analysts to Review Data Presentations at Scientific Conferences during the Week of June 15th